Saturday 17 October 2026
Export GOVX’s income statement to Excel — free account
GeoVax Labs Inc.
GOVX Healthcare Biotechnology
GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 183.4%, EPS grew 88.9% and free cash flow grew 15.8%, each against the same quarter a year earlier.
0.23
0.03
−11.54%
Follow GOVX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (891.59%) | (509.28%) | (483.78%) | (377.44%) |
+8 more TTM periods Free account |
|
| (408.79%) | (309.34%) | (296.11%) | (283.68%) | ||
ROIC |
0.00% | 0.00% | (1,829.11%) | 0.00% | |
Return on Tangible Assets |
(1,319.92%) | (9,035.52%) | (615.60%) | (525.07%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(4.02) | (9.49) | (22.44) | (29.94) | |
Free Cash Flow |
(18.37) | (19.05) | (21.50) | (24.29) | |
Capital Expenditures |
— | — | (0.03) | (0.03) | |
| Other line items | |||||
Cash ROIC |
(374.58%) | (1,078.73%) | (311.13%) | (244.99%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 0.89 | 1.00 | 0.96 | |
Depreciation/Fixed assets |
0.70 | 0.66 | 0.63 | 0.57 | |
Capex/Depreciation |
0.00 | 0.00 | (0.40) | (0.38) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.02) | (9.49) | (22.42) | (29.90) | |
Capex per Share |
0.00 | 0.00 | (0.03) | (0.03) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates